Brief: H Lundbeck: Supportive Phase Ii Results With LU AF82422 In Treatment Of Multiple System Atrophy
Jan 31 (Reuters) - H Lundbeck A/S HLUNb.CO :
* SIGNALS OF EFFICACY ACROSS CLINICAL AND BIOMARKER
ENDPOINTS IN A
SMALL EXPLORATORY PROOF-OF-CONCEPT TRIAL OF 61 MSA PATIENTS
* TREND OF A SLOWING MSA PROGRESSION WAS OBSERVED IN GROUP
EXPOSED
TO LU AF82422
Source text for Eikon: ID:nWkr5D6nM5
Further company coverage: HLUNb.CO
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on H Lundbeck A/S
See all newsEurope Research Roundup: BAWAG Group, Enka Insaat, Partners Group Holding
Brief: CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program
Europe Research Roundup: BNP Paribas, Swedbank, Volkswagen
H Lundbeck steps down from takeover for Avadel, shares rise 3%
Brief: H Lundbeck A/S Says Noted That Our Offer For Acquiring Avadel No Longer Is Considered Superior By Their Board, We Are Currently Considering Our Options